Davie, A., Traoré, S., Giovannitti, M., Pompilio, G., Lambton, M., Cakar, E., & Chatterjee, A. (2023). Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2−, node-positive, high-risk early breast cancer in Italy. Global and Regional Health Technology Assessment, 10(1), 62–69. https://doi.org/10.33393/grhta.2023.2561